Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Interest Expenses (2023 - 2025)

Historic Interest Expenses for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Q3 2025 value amounting to $3.6 million.

  • Harmony Biosciences Holdings' Interest Expenses fell 1672.03% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 1532.38%. This contributed to the annual value of $17.5 million for FY2024, which is 2635.43% down from last year.
  • Harmony Biosciences Holdings' Interest Expenses amounted to $3.6 million in Q3 2025, which was down 1672.03% from $3.6 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Interest Expenses high stood at $7.0 million for Q3 2023, and its period low was $3.6 million during Q3 2025.
  • Moreover, its 3-year median value for Interest Expenses was $4.4 million (2024), whereas its average is $4.8 million.
  • Data for Harmony Biosciences Holdings' Interest Expenses shows a peak YoY increase of 1223.94% (in 2024) and a maximum YoY decrease of 3799.2% (in 2024) over the last 5 years.
  • Harmony Biosciences Holdings' Interest Expenses (Quarter) stood at $4.8 million in 2023, then fell by 12.24% to $4.2 million in 2024, then decreased by 13.97% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.6 million for Q2 2025, and $3.8 million during Q1 2025.